Kelvin brings a wealth of experience in assay development and HTS and strives for excellence in everything he does, said Dr. Norman Garceau, President & CSO.
(PRWEB) October 07, 2011
Blue Sky announced the appointment of Dr. Kelvin Lam as Vice President, Assay Services. Dr. Lam joins Blue Sky with more than 18 years of experience in High Throughput Screening (HTS) and High Content Screening (HCS) of small molecule and natural products. He previously served as Director of HTS at Harvard Stem Cell Institute (HSCI), Harvard University, providing assay development and image-based screening services to Principle Investigators affiliated with HSCI and the Department of Stem Cell and Regenerative Biology (SCRB). In addition to his accomplishments at Harvard, Dr. Lam has an impressive track record of successfully implementing HTS/HCS and related technologies at Pfizer and Scriptgen Pharmaceuticals.
“Kelvin brings a wealth of experience in assay development and HTS and strives for excellence in everything he does”, said Dr. Norman Garceau (President & CSO). “In addition, he has worked in a service capacity within the organizations he has been employed at and, as a result, understands what is required to be an outstanding contract service provider. He is a great addition to the Blue Sky team. “
“Kelvin has been instrumental in making headway in the science of high volume screening against several key druggable gene families including the entire Phosphodiesterase (PDE) and G-protein Coupled Receptors (GPCR) Gene Families at Pfizer,” said Steve Faraci, Ph.D., a member of Blue Sky’s Scientific Advisory Board. “His ability to focus and able to develop elegant assays and his ability to execute HTS by generating high value data will assist Blue Sky to deliver premium quality data on time to the customers”.
Previously, Dr. Lam has authored many peer-reviewed publications and is an inventor on numerous patents. Dr. Lam earned a Ph.D. from Boston University School of Medicine in Biochemistry and completed postdoctoral work in Cancer Genetics at Dana-Farber Cancer Institute and Massachusetts General Hospital Cancer Center affiliated with Harvard Medical School.
Dr. Lam was elected and served from 2004-2008 on the Board of Directors for the Society for Biomolecular Sciences (SBS) and served as Program Chairperson for 2009 and 2011 “Screening Stem Cells Conference”, Society for Laboratory Automation and Screening (SLAS) Global Symposia in Boston, MA. He is a member of the Editorial Board of Journal of Biomolecular Screening (JBS) and Editor-in-Chief of Drug Discovery Today Technologies. He is also a Guest Editor for 2012 JBS Special Issue on Stem Cells. Current interests are in Robotics, Custom Assay Development, High Throughput Screening (HTS) and image based High Content Screening (HCS) assay platforms.
Paul Wengender, CEO of Blue Sky, added that “Kelvin is a perfect cultural and intellectual fit for the Blue Sky BioService Team. We continue to lead the early discovery biology CRO market with aggressive strategic investments in productivity-enhancing technology platforms and people”
About Blue Sky Biotech
Blue Sky Bioservices is a Contract Research Organization (CRO) serving life science industries. As a trusted One-Stop "Gene to Screen" service provider to 9 of Fortune’s Top 10 research-based Pharmaceutical Companies Blue Sky provides a Pathway to Productivity: premium molecular biology, protein expression, scale-up bioprocess, and assay services. Advancing the overall efficiency of the drug discovery process is a central idea behind every service we offer.